Abbott Laboratories dividend calculator – Abbott Laboratories Hikes Dividend Again, Cements ‘Dividend King’ Status
December 29, 2023
🌥️Trending News
Abbott Laboratories ($NYSE:ABT) has cemented its status as a dividend king after announcing that it would raise its dividend yet again. This proves that Abbott Laboratories is committed to providing shareholders with returns on their investment in the form of a steady income in the form of dividends. Abbott Laboratories is a leading global healthcare and pharmaceuticals company, with products in nutrition, diagnostics, medical devices, and branded generic pharmaceuticals.
Dividends – Abbott Laboratories dividend calculator
Abbott Laboratories has again increased its dividend, cementing its position as a “Dividend King”. Looking ahead, investors can expect dividend yields of 1.9%, 1.61%, and 1.54% in 2021, 2022, and 2023 respectively. The average dividend yield over these three years is estimated to be 1.68%. This increase in dividend payouts shows Abbott’s commitment to rewarding its investors and its strong cash flow position.
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Abbott Laboratories. More…
| Total Revenues | Net Income | Net Margin |
| 39.96k | 5.16k | 12.9% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Abbott Laboratories. More…
| Operations | Investing | Financing |
| 7.45k | -1.74k | -7.64k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Abbott Laboratories. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 73.35k | 35.95k | 21.42 |
Key Ratios Snapshot
Some of the financial key ratios for Abbott Laboratories are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 7.4% | 11.6% | 16.3% |
| FCF Margin | ROE | ROA |
| 13.7% | 11.0% | 5.6% |
Share Price
On Thursday, ABBOTT LABORATORIES stock opened at $109.8 and closed at $110.4, up by 0.6% from last closing price of 109.8. This steady increase in share price came after the company hiked its dividend again, cementing its status as a “Dividend King.” This recent hike marks the third time in four quarters the company has raised its payout to shareholders. ABBOTT LABORATORIES is certainly proving its worth as a reliable dividend paying stock. Live Quote…
Analysis
At GoodWhale, we provide an analysis of ABBOTT LABORATORIES‘ financials to help investors make better decisions. Our Star Chart classifieds ABBOTT LABORATORIES as a ‘cow’, a company that has demonstrated a track record of paying out consistent and sustainable dividends. This makes ABBOTT LABORATORIES an ideal investment for income-seeking investors. Additionally, our analysis shows that ABBOTT LABORATORIES is strong in asset, dividend, and profitability and is medium in growth. This indicates that ABBOTT LABORATORIES is a well-rounded, stable investment. Furthermore, ABBOTT LABORATORIES has a high health score of 8/10 with regard to its cashflows and debt, showing that it is capable to safely ride out any crisis without the risk of bankruptcy. Overall, ABBOTT LABORATORIES is an attractive investment for income-seeking investors due to its consistent dividends and strong financials. More…
Peers
Abbott Laboratories is a large, publicly traded company that manufactures and sells medical products, including diagnostics, devices, and branded generic pharmaceuticals. The company has a diversified product portfolio and a strong presence in multiple global markets. However, Abbott Laboratories faces stiff competition from other large medical companies, such as OraSure Technologies Inc, Quidel Corp, and Lucira Health Inc.
– OraSure Technologies Inc ($NASDAQ:OSUR)
OraSure Technologies Inc is a leader in developing, manufacturing, and marketing oral fluid diagnostic products. The company’s products are used for the detection of antibodies to HIV and HCV, as well as for the detection of drugs of abuse. OraSure’s products are sold in over 60 countries worldwide. The company has a market cap of 283.94M as of 2022, a Return on Equity of -8.39%.
OraSure Technologies is dedicated to improving global health by developing and delivering innovative point-of-care diagnostic solutions to meet the needs of underserved populations. The company’s products are used for the detection of infectious diseases, such as HIV and HCV, as well as for the detection of drugs of abuse. OraSure’s products are sold in over 60 countries worldwide.
– Quidel Corp ($NASDAQ:QDEL)
Quidel Corporation is a molecular diagnostics company, providing diagnostic solutions that empower patients and physicians to make better healthcare decisions. The company has a market cap of $5.18 billion and a return on equity of 22.75%. Quidel’s products are used in a variety of settings, including hospitals, physician offices, and retail pharmacies. Quidel’s products are used to diagnose a wide range of conditions, including influenza, respiratory syncytial virus, and tuberculosis. Quidel also offers a variety of point-of-care tests, including tests for pregnancy, ovulation, and infectious diseases.
– Lucira Health Inc ($NASDAQ:LHDX)
Lucira Health Inc is a medical technology company that develops and commercializes molecular diagnostics products. The company’s products are designed to enable earlier and more accurate detection of infectious diseases. Lucira Health’s products include the Lucira COVID-19 All-In-One Test Kit, which is the first FDA-cleared molecular test for the self-collection and detection of COVID-19. The company has a market cap of $46.12 million and a return on equity of -13.64%.
Summary
Abbott Laboratories is a major healthcare company that operates globally and is a well-established dividend payer. Analysts predict that the stock will continue to rise in 2021. However, investors should still conduct their own research and evaluate the company’s risks before making any investments.
Related Posts
Recent Posts
